免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用

摘要/Abstract

摘要：近年来，免疫治疗已成为晚期非小细胞肺癌（NSCLC）治疗的重要组成部分。肿瘤细胞可介导多种免疫逃逸机制躲避机体免疫系统的杀伤，其中程序性死亡蛋白-1及其配体（PD-1/PD-L1）介导的免疫逃逸发挥着关键作用。目前化疗、放疗、分子靶向治疗在晚期NSCLC的治疗中有一定的局限性。近期研究发现PD-1/PD-L1抑制剂与以上治疗综合应用具有一定的协同作用，可增强抗肿瘤效果，进一步延长患者生存期。免疫治疗改变了NSCLC治疗模式，也对受益人群的筛选、治疗相关不良反应的处理带来挑战。总结免疫检查点抑制剂在晚期NSCLC综合治疗中的研究进展，可为NSCLC的最佳治疗方式提供参考依据。

关键词:肺肿瘤,免疫治疗,PD-1/PD-L1,综合治疗

Abstract:In recent years, immunotherapy has become an important part of the treatment for advanced non-small cell lung cancer (NSCLC). Tumor cells can escape from the body′s immune system by mediating various immune escape mechanisms, among which programmed death-1/programmed death ligand-1 (PD-1/PD-L1) mediated immune escape plays an important role. Currently, chemotherapy, radiotherapy and molecular targeted therapy have certain limitations in the treatment of advanced NSCLC. Recent studies have found that the combined application of PD-1/PD-L1 inhibitor and other treatment methods has certain synergistic effect, thus enhances the anti-tumor effect and further prolongs the survival of patients. Immunotherapy brings not only changes in the treatment patterns of NSCLC, but also challenges in the screening of target population and the management of treatment-related adverse reactions. Summarizing the research progress on immune checkpoint inhibitors in the comprehensive treatment of advanced NSCLC can provide reference for the best treatment of NSCLC.

Key words:Lung neoplasms,Immunotherapy,PD-1/PD-L1,Comprehensive therapy

白馨雅, 张金梦, 孙洋, 安永恒. 免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(8): 500-504.

Bai Xinya, Zhang jinmeng, Sun Yang, An Yongheng . Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(8): 500-504.

参考文献

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492. ［2］ Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments［J］. Lancet, 2017, 389(10066): 299-311. DOI: 10.1016/S0140-6736(16)30958-8. ［3］ Borghaei H, Pazares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643. ［4］ Reck M, Rodriguezabreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer［J］. N Engl J Med, 2016, 375(19): 1823-1833. DOI: 10.1056/NEJMoa1606774. ［5］ Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial［J］. Lancet, 2016, 387(10030): 1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. ［6］ Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization［J］. Cell, 2018, 175(2): 313-326. DOI: 10.1016/j.cell.2018.09.035. ［7］ Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point［J］. Nature, 2017, 541(7637): 321-330. DOI: 10.1038/nature21349. ［8］ Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer［J］. J Clin Oncol, 2016, 34(25): 2969-2979. DOI: 10.1200/JCO.2016.66.9861. ［9］ PazAres L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer［J］. N Engl J Med, 2018, 379(21): 2040-2051. DOI: 10.1056/NEJMoa1810865. ［10］ Gandhi L, RodriguezAbreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer［J］. N Engl J Med, 2018, 378(22): 2078-2092. DOI: 10.1056/NEJMoa1801005. ［11］ Rivero L, Bunn B. Impower132 study shows atezolizumab in combinationwith carboplatin and pemetrexed reduced the risk of disease worsening or death (PFS) instage Ⅳ non squamous NSCLC［EB/OL］. ［2018-09-28］.http://www.ascopost.com/News/59093. ［12］ Sharabi AB, Lim M, Deweese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy［J］. Lancet Oncol, 2015, 16(13): e498-e509. DOI: 10.1016/S1470-2045(15)00007-8. ［13］ Gong J, Le TQ, Massarelli E, et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination［J］. J Immunother Cancer, 2018, 6(1): 46. DOI: 10.1186/s40425-018-0361-7. ［14］ Yuan Z, Fromm A, Ahmed KA, et al. Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1-negative metastatic squamous cell carcinoma of the lung［J］. J Thorac Oncol, 2017, 12(9): e135-e136. DOI: 10.1016/j.jtho.2017.04.029. ［15］ Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial［J］. Lancet Oncol, 2017, 18(7): 895-903. DOI: 10.1016/S1470-2045(17)30380-7. ［16］ Kotecha R, Kim JM, Miller JA, et al. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis［J］. Neuro Oncol, 2019, pii: noz046. DOI: 10.1093/neuonc/noz046. ［17］ Blake Z, Marks DK, Gartrell RD, et al. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition［J］. J Immunother Cancer, 2018, 6(1): 25. DOI: 10.1186/s40425-018-0338-6. ［18］ Schapira E, Hubbeling H, Yeap BY, et al. Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases［J］. Int J Radiat Oncol Biol Phys, 2018, 101(3): 624-629. DOI: 10.1016/j.ijrobp.2018.02.175. ［19］ Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2017, 98(2): 344-351. DOI: 10.1016/j.ijrobp.2017.02.003. ［20］ Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study［J］. Lancet Oncol, 2017, 18(1): 31-41. DOI: 10.1016/S1470-2045(16)30624-6. ［21］ Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden［J］. N Engl J Med, 2018, 378(22): 2093-2104. DOI: 10.1056/NEJMoa1801946. ［22］ Ready N, Hellmann MD, Awad MM, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes byprogrammed death ligand 1 and tumor mutational burden as biomarkers［J］. J Clin Oncol, 2019, 37(12): 992-1000. DOI: 10.1200/JCO.18.01042. ［23］ Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges［J］. Nat Rev Clin Oncol, 2018, 15(5): 325-340. DOI: 10.1038/nrclinonc.2018.29. ［24］ Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia［J］. Cancer Cell, 2014, 26(5): 605-622. DOI: 10.1016/j.ccell.2014.10.006. ［25］ Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC［J］. N Engl J Med, 2018, 378(24): 2288-2301. DOI: 10.1056/NEJMoa1716948. ［26］ Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)［J］. J Thorac Oncol, 2014, 9(2): 154-162. DOI: 10.1097/JTO.0000000000000033. ［27］ Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer［J］. N Engl J Med, 2017, 376(7): 629-640. DOI: 10.1056/NEJMoa1612674. ［28］ Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer［J］. JAMA Oncol, 2018, 4(8): 1112-1115. DOI: 10.1001/jamaoncol.2017.4526. ［29］ Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy［J］. Nat Rev Cancer, 2014, 14(3): 199-208. DOI: 10.1038/nrc3672. ［30］ Chang X, Lu X, Guo J, et al. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy［J］. Cancer Treat Rev, 2019, 74: 49-60. DOI: 10.1016/j.ctrv.2018.08.006. ［31］ Backlund M, Freedman J. Microwave ablation and immune activation in the treatment of recurrent colorectal lung metastases: a case report［J］. Case Rep Oncol, 2017, 10(1): 383-387. DOI: 10.1159/000468982. ［32］ Guo Z, Meng C, Wei X, et al. Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: a case report［J］. Thorac Cancer, 2018, 9(5): 646-651. DOI: 10.1111/1759-7714.12600.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	贺嘉慧, 胡钦勇.基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[6]	吕璐, 孙鹏飞.肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[7]	李雄安, 颜艳艳.丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[8]	黄华玉, 龚虹云, 宋启斌.胸部放疗联合免疫治疗时代肺炎发生的影响因素[J]. 国际肿瘤学杂志, 2023, 50(2): 102-106.
[9]	张雨潇, 张连生, 李莉娟.新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景[J]. 国际肿瘤学杂志, 2023, 50(2): 122-125.
[10]	张碧霞, 丁江华.EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101.
[11]	左小平, 刘晓川, 吴西强, 李周, 夏天, 刘国凤.老年早期肺癌患者经胸腔镜肺切除术后心律失常发生的危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(12): 711-716.
[12]	陈郁, 许华, 刘海, 陈士新.基于CT影像学特征的恶性肺纯磨玻璃结节患者病理分型预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(11): 655-660.
[13]	张万芳, 王尤, 苏晶, 陈刚, 周福祥.肺原发尤文肉瘤/原始神经外胚层瘤1例[J]. 国际肿瘤学杂志, 2023, 50(1): 62-64.
[14]	杨莎, 杨晓华, 王苏华, 薛晓燕, 徐俊.老年肺癌胸腔镜手术后下肢深静脉血栓的危险因素分析及预测模型的建立和验证[J]. 国际肿瘤学杂志, 2022, 49(9): 532-536.
[15]	王津, 张耀圣, 孙婷婷, 王丹, 胡乃东.以前胸壁聚集性多发蕈状肿物为表现的肺腺鳞状细胞癌皮肤转移1例[J]. 国际肿瘤学杂志, 2022, 49(9): 575-576.